首页> 外文期刊>The Tohoku Journal of Experimental Medicine >PINK1 Expression Is Associated with Poor Prognosis in Lung Adenocarcinoma
【24h】

PINK1 Expression Is Associated with Poor Prognosis in Lung Adenocarcinoma

机译:Pink1表达与肺腺癌预后不良有关

获取原文
获取原文并翻译 | 示例
           

摘要

PTEN-induced putative kinase protein 1 (PINK1) is a serine/threonine-protein kinase that phosphorylates mitochondrial proteins and is involved in mitophagy. Thus, PINK1 may protect cancer cells against mitochondrial dysfunction during cellular stress. However, the role of PINK1 in lung cancer was rarely explored. In this study, we immunohistochemically analyzed the expression of PINK1 in 256 patients with non-small-cell lung cancer, consisting of 137 patients with adenocarcinoma (AC) and 119 patients with squamous cell carcinoma (SCC). In particular, we focused on the difference in diagnostic or prognostic value of PINK1 expression between AC patients and SCC patients. The patients with AC or SCC were divided into high or low PINK1 expression group, according to the immunohistochemical score that was based on the percentage of PINK1 positive cells and staining intensity. Among the 137 AC specimens, 52 specimens (37.96%) were judged as high PINK1 expression, and likewise, among 119 SCC specimens, 42 specimens (35.29%) were judged as high PINK1 expression. Importantly, high PINK1 expression was significantly associated with postoperative chemoresistance of AC, but not in case of SCC. Moreover, high PINK1 expression was identified as a poor prognostic factor for AC, but not for SCC. These results may reflect the biological difference between AC and SCC. In conclusion, high PINK1 expression is correlated with poor response to chemotherapy and is an independent prognostic factor for AC, but not for SCC. Our findings suggest that PINK1 detection could help stratify patients who may have poor response to chemotherapy and guide the individual treatment.
机译:PTEN诱导的推定激酶蛋白1(PINK1)是一种丝氨酸/苏氨酸蛋白激酶,其磷酸化线粒体蛋白并参与乳化物。因此,粉红色1可以在细胞应激期间保护癌细胞免受线粒体功能障碍。然而,粉红色1在肺癌中的作用很少探索。在这项研究中,我们免疫组织化学分析了256例非小细胞肺癌患者粉红色1的表达,由137例腺癌(AC)和119例鳞状细胞癌(SCC)组成。特别是,我们专注于AC患者和SCC患者PINK1表达的诊断或预后值差异。根据基于PINK1阳性细胞和染色强度的百分比,患有AC或SCC的患者分为高或低粉红色的表达组。在137个AC标本中,52个标本(37.96%)被判断为高粉红色的表达,同样,在119个SCC标本中,42个标本(35.29%)被判断为高粉红色的表达。重要的是,高Pink1表达与AC的术后化学抑制显着相关,但不适用于SCC。此外,鉴定了高Pink1表达作为AC的预后不良因子,但不适用于SCC。这些结果可以反映AC和SCC之间的生物学差异。总之,高粉红色1表达与对化疗的不良反应相关,是AC的独立预后因素,但不适用于SCC。我们的研究结果表明,Pink1检测可以帮助分层可能对化疗较差并指导个体治疗的患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号